Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ALIROCUMAB Cause Post procedural complication? 12 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Post procedural complication have been filed in association with ALIROCUMAB (Praluent). This represents 0.1% of all adverse event reports for ALIROCUMAB.

12
Reports of Post procedural complication with ALIROCUMAB
0.1%
of all ALIROCUMAB reports
1
Deaths
4
Hospitalizations

How Dangerous Is Post procedural complication From ALIROCUMAB?

Of the 12 reports, 1 (8.3%) resulted in death, 4 (33.3%) required hospitalization, and 1 (8.3%) were considered life-threatening.

Is Post procedural complication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ALIROCUMAB. However, 12 reports have been filed with the FAERS database.

What Other Side Effects Does ALIROCUMAB Cause?

Myalgia (1,571) Product dose omission (1,354) Injection site pain (1,220) Muscle spasms (1,113) Arthralgia (993) Fatigue (922) Pain (892) Pain in extremity (888) Product dose omission issue (864) Injection site bruising (821)

What Other Drugs Cause Post procedural complication?

ADALIMUMAB (2,494) ETANERCEPT (318) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (244) UPADACITINIB (241) RISANKIZUMAB-RZAA (232) INFLIXIMAB (217) METHOTREXATE (188) TREPROSTINIL (174) HUMAN IMMUNOGLOBULIN G (159) PREDNISONE (157)

Which ALIROCUMAB Alternatives Have Lower Post procedural complication Risk?

ALIROCUMAB vs ALISKIREN ALIROCUMAB vs ALISKIREN HEMIFUMARATE ALIROCUMAB vs ALISKIREN\HYDROCHLOROTHIAZIDE ALIROCUMAB vs ALIZAPRIDE ALIROCUMAB vs ALLANTOIN

Related Pages

ALIROCUMAB Full Profile All Post procedural complication Reports All Drugs Causing Post procedural complication ALIROCUMAB Demographics